This study implied that trastuzumab could be safely added to preoperative chemo(immuno)therapy, and this regimen induced a TRG0/1 rate of 33.3% in patients with potentially resectable stage III to IVB HER2-positive GC. This evidence concerns the gene ERBB2 and gastric cancer.